Amyotrophic Lateral Sclerosis (ALS)

Neurology

Overview

Definition

A rapidly progressive, fatal neurodegenerative disease that selectively destroys both upper and lower motor neurons.

Epidemiology

Most common motor neuron disease. Average age of onset is 55-75. Survival is typically 3-5 years from symptom onset.

Etiology & Risk Factors

  • Mostly sporadic (90%).
  • Familial cases (10%) linked to mutations in SOD1, C9orf72, or TDP-43.

Clinical Symptoms

  • Asymmetric limb weakness (often starting with hand clumsiness or foot drop)
  • Upper Motor Neuron (UMN) signs: Spasticity, hyperreflexia, Babinski sign
  • Lower Motor Neuron (LMN) signs: Muscle atrophy, fasciculations (twitching), weakness
  • Bulbar involvement: Dysarthria, dysphagia, pseudobulbar affect (inappropriate laughing/crying)
  • Sensation and eye movements are typically SPARED.

Clinical Approach

Diagnosis

  • Clinical diagnosis based on the presence of UMN and LMN signs in multiple body regions
  • EMG: Evidence of active and chronic denervation (fibrillation potentials, fasciculations) across multiple spinal segments
  • Must rule out structural lesions (cervical myelopathy) via MRI

Management

  • No cure exists.
  • Riluzole (Glutamate antagonist): Prolongs survival by a few months
  • Edaravone (free radical scavenger): May slow clinical decline in early disease
  • Non-invasive ventilation (BiPAP) significantly improves quality of life and survival
  • PEG tube placement for severe dysphagia

Complications

  • Respiratory failure (invariably the cause of death)
  • Malnutrition (due to severe dysphagia)